Lemaitre Vascular (LMAT) Common Equity (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Common Equity data on file, last reported at $406.6 million in Q1 2026.

• Common Equity for Q1 2026 came in at $406.6 million, up 16.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $406.6 million (up 16.99% YoY), and the FY2025 annual result was $393.5 million, up 16.67% from the prior year.
• Common Equity rose to $406.6 million in Q1 2026 per LMAT's latest filing, from $393.5 million in the prior quarter.
• Over five years, Common Equity peaked at $406.6 million in Q1 2026 and troughed at $257.8 million in Q1 2022.
• A 5-year average of $316.2 million and a median of $308.5 million in 2024 frame the typical range for Common Equity.
• On a YoY basis, Common Equity climbed as much as 45.21% in 2022 and fell as far as 4.9% in 2022.
• A 5-year view of Common Equity shows it stood at $268.2 million in 2022, then climbed by 11.07% to $297.9 million in 2023, then climbed by 13.22% to $337.3 million in 2024, then climbed by 16.67% to $393.5 million in 2025, then gained by 3.33% to $406.6 million in 2026.
• Business Quant data shows LMAT's Common Equity at $406.6 million in Q1 2026, $393.5 million in Q4 2025, and $378.9 million in Q3 2025.